References
1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37 (12): 1595–607. DOI: https://doi.org/10.2337/diab.37.12.1595
2. Gallagher E.J., LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer. 2020; 20 (11): 629–44. DOI: https://doi.org/10.1038/s41568-020-0295-5
3. Avgerinos K.I., Spyrou N., Mantzoros C.S., Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism. 2019; 92: 121–35. DOI: https://doi.org/10.1016/j.metabol.2018.11.001
4. Zhang A.M.Y., Wellberg E.A., Kopp J.L., Johnson J.D. Hyperinsulinemia in obesity, inflammation, and cancer. Diabetes Metab J. 2021; 45 (3): 285–311. DOI: https://doi.org/10.4093/dmj.2020.0250
5. Berlanga-Acosta J., Guillén-Nieto G., Rodríguez-Rodríguez N., Bringas-Vega M.L., García-Del-Barco-Herrera D., Berlanga-Saez J.O., et al. Insulin resistance at the crossroad of alzheimer disease pathology: a review. Front Endocrinol (Lausanne). 2020; 11: 560375. DOI: https://doi.org/10.3389/fendo.2020.560375
6. Cleasby M.E., Jamieson P.M., Atherton P.J. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol. 2016; 229 (2): R67–81. DOI: https://doi.org/10.1530/JOE-15-0533
7. Tchetina E.V., Markova G.A., Sharapova E.P. Insulin resistance in osteoarthritis: similar mechanisms to type 2 diabetes mellitus. J Nutr Metab. 2020; 2020: 4143802. DOI: https://doi.org/10.1155/2020/4143802
8. Petersen M.C., Shulman G.I. Mechanisms of insulin action and insulin resistance. Physiol Rev. 2018; 98 (4): 2133–223. DOI: https://doi.org/10.1152/physrev.00063.2017
9. Crofts C.A.P., Zinn C., Wheldon M., Schofield G. Hyperinsulinemia: a unifying theory of chronic disease? Diabesity. 2015; 1 (4): 34–43. DOI: https://doi.org/10.15562/diabesity.2015.19
10. Saltiel A.R. Insulin signaling in health and disease. J Clin Invest. 2021; 131 (1): e142241. DOI: https://doi.org/10.1172/JCI142241
11. Nolan C.J., Prentki M. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: time for a conceptual framework shift. Diab Vasc Dis Res. 2019; 16 (2): 118–27. DOI: https://doi.org/10.1177/1479164119827611
12. Holt S.H., Miller J.C., Petocz P. An insulin index of foods: the insulin demand generated by 1000-kJ portions of common foods. Am J Clin Nutr. 1997; 66 (5): 1264–76. DOI: https://doi.org/10.1093/ajcn/66.5.1264
13. Kraft J.R. Detection of diabetes mellitus in situ (occult diabetes). Lab Med. 1975; 6 (2): 10–22. DOI: https://doi.org/10.1093/labmed/6.2.10
14. Templeman N.M., Skovsø S., Page M.M., Lim G.E., Johnson J.D. A causal role for hyperinsulinemia in obesity. J Endocrinol. 2017; 232 (3): R173–83. DOI: https://doi.org/10.1530/JOE-16-0449
15. Bell K.J., Gray R., Munns D., Petocz P., Howard G., Colagiuri S., et al. Estimating insulin demand for protein-containing foods using the food insulin index. Eur J Clin Nutr. 2014; 68 (9): 1055–9. DOI: https://doi.org/10.1038/ejcn.2014.126
16. Dubnov G., Berry E.M. Omega-6 fatty acids and coronary artery disease: the pros and cons. Curr Atheroscler Rep. 2004; 6 (6): 441–6. DOI: https://doi.org/10.1007/s11883-004-0084-8
17. Van Cauter E., Shapiro E.T., Tillil H., Polonsky K.S. Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm. Am J Physiol. 1992; 262 (4 pt 1): E467–75. DOI: https://doi.org/10.1152/ajpendo.1992.262.4.E467
18. Jakubowicz D., Barnea M., Wainstein J., Froy O. High caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women. Obesity (Silver Spring). 2013; 21 (12): 2504–12. DOI: https://doi.org/10.1002/oby.20460
19. Kyriazis G.A., Soundarapandian M.M., Tyrberg B. Sweet taste receptor signaling in beta cells mediates fructose-induced potentiation of glucose-stimulated insulin secretion. Proc Natl Acad Sci USA. 2012; 109 (8): E524–32. DOI: https://doi.org/10.1073/pnas.1115183109
20. Güemes A., Herrero P., Bondia J., Georgiou P. Modeling the effect of the cephalic phase of insulin secretion on glucose metabolism. Med Biol Eng Comput. 2019; 57 (6): 1173–86. DOI: https://doi.org/10.1007/s11517-019-01950-x
21. Weir G.C., Bonner-Weir S. Five stages of evolving beta-cell dysfunction during progression to diabetes. Diabetes. 2004; 53 (suppl 3): S16–21. DOI: https://doi.org/10.2337/diabetes.53.suppl_3.s16
22. Cani P.D., Amar J., Iglesias M.A., Poggi M., Knauf C., Bastelica D., et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007; 56 (7): 1761–72. DOI: https://doi.org/10.2337/db06-1491
23. Baumgard L.H., Hausman G.J., Sanz Fernandez M.V. Insulin: pancreatic secretion and adipocyte regulation. Domest Anim Endocrinol. 2016; 54: 76–84. DOI: https://doi.org/10.1016/j.domaniend.2015.07.001
24. Teegarden D., Donkin S.S. Vitamin D: emerging new roles in insulin sensitivity. Nutr Res Rev. 2009; 22 (1): 82–92. DOI: https://doi.org/10.1017/S0954422409389301
25. Sung C.C., Liao M.T., Lu K.C., Wu C.C. Role of vitamin D in insulin resistance. J Biomed Biotechnol. 2012; 2012: 634195. DOI: https://doi.org/10.1155/2012/634195
26. Chiu K.C., Chu A., Go V.L., Saad M.F. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004; 79 (5): 820–5. DOI: https://doi.org/10.1093/ajcn/79.5.820
27. Deleskog A., Hilding A., Brismar K., Hamsten A., Efendic S., Östenson C.G. Low serum 25-hydroxyvitamin D level predicts progression to type 2 diabetes in individuals with prediabetes but not with normal glucose tolerance. Diabetologia. 2012; 55 (6): 1668–78. DOI: https://doi.org/10.1007/s00125-012-2529-x
28. Forouhi N.G., Ye Z., Rickard A.P., Khaw K.T., Luben R., Langenberg C., et al. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia. 2012; 55 (8): 2173–82. DOI: https://doi.org/10.1007/s00125-012-2544-y
29. Szymczak-Pajor I., Drzewoski J., Śliwińska A. The Molecular mechanisms by which vitamin D prevents insulin resistance and associated disorders. Int J Mol Sci. 2020; 21 (18): 6644. DOI: https://doi.org/10.3390/ijms21186644
30. Kahleova H., Belinova L., Malinska H., Oliyarnyk O., Trnovska J., Skop V., et al. Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover study. Diabetologia. 2014; 57 (8): 1552–60. DOI: https://doi.org/10.1007/s00125-014-3253-5
31. Janssen J.A.M.J.L. Hyperinsulinemia and its pivotal role in aging, obesity, type 2 diabetes, cardiovascular disease and cancer. Int J Mol Sci. 2021; 22 (15): 7797. DOI: https://doi.org/10.3390/ijms22157797
32. Mortera R.R., Bains Y., Gugliucci A. Fructose at the crossroads of the metabolic syndrome and obesity epidemics. Front Biosci (Landmark Ed). 2019; 24: 186–211. DOI: https://doi.org/10.2741/4713
33. Schwarz J.M., Noworolski S.M., Erkin-Cakmak A., Korn N.J., Wen M.J., Tai V.W., et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology. 2017; 153 (3): 743–52. DOI: https://doi.org/10.1053/j.gastro.2017.05.043
34. Rao M.N., Chau A., Madden E., Inslicht S., Talbot L., Richards A., et al. Hyperinsulinemic response to oral glucose challenge in individuals with posttraumatic stress disorder. Psychoneuroendocrinology. 2014; 49: 171–81. DOI: https://doi.org/10.1016/j.psyneuen.2014.07.006
35. Mounier C., Posner B.I. Transcriptional regulation by insulin: from the receptor to the gene. Can J Physiol Pharmacol. 2006; 84 (7): 713–24. DOI: https://doi.org/10.1139/y05-152
36. Rahman M.S., Hossain K.S., Das S., Kundu S., Adegoke E.O., Rahman M.A., et al. Role of insulin in health and disease: an update. Int J Mol Sci. 2021; 22 (12): 6403. DOI: https://doi.org/10.3390/ijms22126403
37. Ludwig D.S., Ebbeling C.B. The carbohydrate-insulin model of obesity: beyond «calories in, calories out». JAMA Intern Med. 2018; 178 (8): 1098–103. DOI: https://doi.org/10.1001/jamainternmed.2018.2933
38. Non-alcoholic Fatty Liver Disease: a 360-degree Overview. In: E. Bugianesi (ed.). Springer Nature, 2020: 362 р. ISBN 978-3-319-95827-9 DOI: https://doi.org/10.1007/978-3-319-95828-6
39. Reyes-Farias M., Fos-Domenech J., Serra D., Herrero L., Sánchez-Infantes D. White adipose tissue dysfunction in obesity and aging. Biochem Pharmacol. 2021; 192: 114723. DOI: https://doi.org/10.1016/j.bcp.2021.114723
40. Ruderman N.B., Carling D., Prentki M., Cacicedo J.M. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest. 2013; 123 (7): 2764–72. DOI: https://doi.org/10.1172/JCI67227
41. Grahame Hardie D. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med. 2014; 276 (6): 543–59. DOI: https://doi.org/10.1111/joim.12268
42. Boucher J., Kleinridders A., Kahn C.R. Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 2014; 6 (1): a009191. DOI: https://doi.org/10.1101/cshperspect.a009191
43. Ye J. Mechanism of insulin resistance in obesity: a role of ATP. Front Med. 2021; 15 (3): 372–82. DOI: https://doi.org/10.1007/s11684-021-0862-5
44. Barber T.M., Kyrou I., Randeva H.S., Weickert M.O. Mechanisms of insulin resistance at the crossroad of obesity with associated metabolic abnormalities and cognitive dysfunction. Int J Mol Sci. 2021; 22 (2): 546. DOI: https://doi.org/10.3390/ijms22020546
45. Rachfal A.W., Grant S.F.A., Schwartz S.S. The diabetes syndrome – a collection of conditions with common, interrelated pathophysiologic mechanisms. Int J Gen Med. 2021; 14: 923–36. DOI: https://doi.org/10.2147/IJGM.S305156
46. Scholz G.H., Hanefeld M. Metabolic vascular syndrome: new insights into a multidimensional network of risk factors and diseases. Visc Med. 2016; 32 (5): 319–26. DOI: https://doi.org/10.1159/000450866
47. Whaley-Connell A., Sowers J.R. Insulin resistance in kidney disease: is there a distinct role separate from that of diabetes or obesity? Cardiorenal Med. 2017; 8 (1): 41–9. DOI: https://doi.org/10.1159/000479801
48. Furman D., Campisi J., Verdin E., Carrera-Bastos P., Targ S., Franceschi C., et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019; 25 (12): 1822–32. DOI: https://doi.org/10.1038/s41591-019-0675-0
49. Pagotto U. Where does insulin resistance start? The brain. Diabetes Care. 2009; 32 (suppl 2): S174–7. DOI: https://doi.org/10.2337/dc09-S305
50. Barrett E.J., Liu Z. The endothelial cell: an «early responder» in the development of insulin resistance. Rev Endocr Metab Disord. 2013; 14 (1): 21–7. DOI: https://doi.org/10.1007/s11154-012-9232-6
51. Kwaifa I.K., Bahari H., Yong Y.K., Noor S.M. Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications. Biomolecules. 2020; 10 (2): 291. DOI: https://doi.org/10.3390/biom10020291
52. Colognesi M., Gabbia D., De Martin S. Depression and cognitive impairment-extrahepatic manifestations of NAFLD and NASH. Biomedicines. 2020; 8 (7): 229. DOI: https://doi.org/10.3390/biomedicines8070229
53. Spinelli M., Fusco S., Grassi C. Brain insulin resistance and hippocampal plasticity: mechanisms and biomarkers of cognitive decline. Front Neurosci. 2019; 13: 788. DOI: https://doi.org/10.3389/fnins.2019.00788
54. Geisler C.E., Renquist B.J. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones. J Endocrinol. 2017; 234 (1): R1–21. DOI: https://doi.org/10.1530/JOE-16-0513
55. Buie J.J., Watson L.S., Smith C.J., Sims-Robinson C. Obesity-related cognitive impairment: the role of endothelial dysfunction. Neurobiol Dis. 2019; 132: 104580. DOI: https://doi.org/10.1016/j.nbd.2019.104580
56. Dada T. Is glaucoma a neurodegeneration caused by central insulin resistance: diabetes type 4? J Curr Glaucoma Pract. 2017; 11 (3): 77–9. DOI: https://doi.org/10.5005/jp-journals-10028-1228
57. Roddy G.W., Rosa R.H., Viker K.B., Holman B.H., Hann C.R., Krishnan A., et al. Diet mimicking «fast food» causes structural changes to the retina relevant to age-related macular degeneration. Curr Eye Res. 2020; 45 (6): 726–32. DOI: https://doi.org/10.1080/02713683.2019.1694156
58. Rudnicka E., Suchta K., Grymowicz M., Calik-Ksepka A., Smolarczyk K., Duszewska A.M., et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021; 22 (7): 3789. DOI: https://doi.org/10.3390/ijms22073789
59. Borel A.L. Sleep apnea and sleep habits: relationships with metabolic syndrome. Nutrients. 2019; 11 (11): 2628. DOI: https://doi.org/10.3390/nu11112628
60. Pite H., Aguiar L., Morello J., Monteiro E.C., Alves A.C., Bourbon M., Morais-Almeida M. Metabolic dysfunction and asthma: current perspectives. J Asthma Allergy. 2020; 13: 237–47. DOI: https://doi.org/10.2147/JAA.S208823.
61. Hamer J.A., Testani D., Mansur R.B., Lee Y., Subramaniapillai M., McIntyre R.S. Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression. Exp Neurol. 2019; 315: 1–8. DOI: https://doi.org/10.1016/j.expneurol.2019.01.016
62. Calkin C.V. Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Ann Med. 2019; 51 (5–6): 281–93. DOI: https://doi.org/10.1080/07853890.2019.1659511
63. Nam S.Y. Obesity-related digestive diseases and their pathophysiology. Gut Liver. 2017; 11 (3): 323–334. DOI: https://doi.org/10.5009/gnl15557
64. Hu Y., Zhu Y., Lian N., Chen M., Bartke A., Yuan R. Metabolic syndrome and skin diseases. Front Endocrinol (Lausanne). 2019; 10: 788. DOI: https://doi.org/10.3389/fendo.2019.00788
65. Cooper I.D., Crofts C.A.P., DiNicolantonio J.J., Malhotra A., et al. Relationships between hyperinsulinaemia, magnesium, vitamin D, thrombosis and COVID-19: rationale for clinical management. Open Heart. 2020; 7 (2): e001356. DOI: https://doi.org/10.1136/openhrt-2020-001356
66. Montefusco L., Ben Nasr M., D’Addio F., Loretelli C., et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021; 3 (6): 774–85. DOI: https://doi.org/10.1038/s42255-021-00407-6
67. Tanase D.M., Gosav E.M., Neculae E., Costea C.F., et al. hypothyroidism-induced nonalcoholic fatty liver disease (hin): mechanisms and emerging therapeutic options. Int J Mol Sci. 2020; 21 (16): 5927. DOI: https://doi.org/10.3390/ijms21165927
68. Li A.A., Ahmed A., Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020; 14 (2): 168–78. DOI: https://doi.org/10.5009/gnl19069